Amalgamated Bank lowered its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 0.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 224,433 shares of the biotechnology company’s stock after selling 2,060 shares during the quarter. Amalgamated Bank owned about 0.07% […]
Exelixis (NASDAQ:EXEL – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation. Analyst Recommendations This is a summary of recent ratings […]
Exelixis, Inc. (NASDAQ:EXEL) Q4 2023 Earnings Call Transcript February 6, 2024 Exelixis, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results Conference […]